Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

$24.99

Economic Value Added (EVA)

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

AbbVie Inc., economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial analysis reveals notable fluctuations in several key performance indicators over the five-year period under review.

Net Operating Profit After Taxes (NOPAT)
The NOPAT experienced a significant increase from 4,455 million US dollars in 2020 to a peak of 12,362 million US dollars in 2021. This was followed by a slight decline to 11,543 million US dollars in 2022. However, there was a sharp decrease in 2023 to 3,292 million US dollars, before a modest recovery to 4,563 million US dollars in 2024. This pattern indicates high volatility in operating profitability with a peak in 2021 and a substantial drop thereafter.
Cost of Capital
The cost of capital showed a steady upward trend throughout the period, rising from 7.88% in 2020 to 9.57% in 2024. This incremental increase suggests a growing expense associated with financing, potentially reflecting changes in market conditions or increased perceived risk.
Invested Capital
Invested capital consistently declined from 103,725 million US dollars in 2020 to 68,204 million US dollars in 2023. A slight increase to 69,263 million US dollars was observed in 2024. This downward trend in capital investment indicates a reduction in the asset base or capital commitments, which may be a result of strategic divestment, operational efficiency, or asset sales.
Economic Profit
The economic profit metric, which considers both operating profit and cost of capital, showed a corresponding fluctuation. It moved from a negative figure of -3,721 million US dollars in 2020 to a positive peak of 4,013 million in 2021, remaining positive at 3,894 million in 2022. Subsequently, economic profit turned negative again with -3,207 million in 2023 and -2,068 million in 2024. This oscillation highlights periods of value creation followed by value erosion, closely aligned with the patterns seen in NOPAT and cost of capital.

In summary, the financial performance exhibited considerable variability, with 2021 being a notably strong year. The rise in the cost of capital alongside decreases in invested capital and economic profit in the latter years may indicate increased challenges in generating returns above the cost of financing. The firm appears to face pressures on profitability and capital efficiency in recent years, warranting further analysis into operational factors and market environment impacts.


Net Operating Profit after Taxes (NOPAT)

AbbVie Inc., NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net earnings attributable to AbbVie Inc.
Deferred income tax expense (benefit)1
Increase (decrease) in restructuring reserve2
Increase (decrease) in equity equivalents3
Interest expense
Interest expense, operating lease liability4
Adjusted interest expense
Tax benefit of interest expense5
Adjusted interest expense, after taxes6
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income7
Investment income, after taxes8
Net income (loss) attributable to noncontrolling interest
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in restructuring reserve.

3 Addition of increase (decrease) in equity equivalents to net earnings attributable to AbbVie Inc..

4 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

5 2024 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

6 Addition of after taxes interest expense to net earnings attributable to AbbVie Inc..

7 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

8 Elimination of after taxes investment income.


The financial data reveals significant fluctuations in key profitability metrics over the five-year period from 2020 to 2024. Net earnings attributable to the company show a marked increase between 2020 and 2021, more than doubling from 4,616 million USD to 11,542 million USD. This upward trend continued slightly into 2022, reaching 11,836 million USD. However, a sharp decline is observed in 2023, where net earnings drop to 4,863 million USD, followed by a further decrease in 2024 to 4,278 million USD.

Similarly, net operating profit after taxes (NOPAT) exhibits a strong growth trajectory in the initial years, rising from 4,455 million USD in 2020 to 12,362 million USD in 2021, before slightly decreasing to 11,543 million USD in 2022. In contrast to the early upward momentum, NOPAT experiences a significant fall in 2023 to 3,292 million USD, although it recovers somewhat in 2024 to 4,563 million USD.

Net Earnings Attributable to the Company
Demonstrated substantial growth in the first two years, peaking in 2022.
Experienced a pronounced decline in the subsequent years, reaching the lowest point in 2024 within the presented timeframe.
Net Operating Profit After Taxes (NOPAT)
Followed a similar pattern to net earnings, with rapid growth through 2021, slight reduction in 2022.
Showed a sharp decline beginning in 2023, with modest recovery in 2024 albeit remaining well below earlier peak levels.

Overall, the data points toward a period of strong profitability gains up to 2022, followed by notable erosion in both net earnings and NOPAT over the last two years. The decline in profitability metrics during 2023 and 2024 suggests the presence of operational challenges or market conditions adversely impacting financial performance. The partial resurgence of NOPAT in 2024 hints at potential stabilization or early signs of financial recovery.


Cash Operating Taxes

AbbVie Inc., cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Income tax expense (benefit)
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Income Tax Expense (Benefit) Trend
The income tax expense exhibited significant volatility over the analyzed period. It began with a notable benefit of -$1,224 million at the end of 2020, indicating a tax gain or credit that reduced tax burden during that year. This reversed sharply in 2021 to a tax expense of $1,440 million, then further increased to $1,632 million in 2022. In 2023, it slightly decreased but remained high at $1,377 million. However, in 2024, the income tax expense again turned negative, showing a benefit of -$570 million. This pattern suggests fluctuating tax positions or adjustments possibly due to changes in tax regulations, earnings variations, or deferred tax accounting impacts.
Cash Operating Taxes Trend
The cash operating taxes consistently increased from 2020 through 2023, indicating increasing cash payments for taxes despite fluctuations in reported income tax expense. In 2020, cash taxes were $1,585 million, which rose significantly each year to reach $4,625 million in 2023. However, in 2024, there was a notable decline in cash operating taxes to $1,339 million, which is substantially lower than the prior years. This decline could suggest a one-time tax payment adjustment, changes in taxable income, tax credits utilization, or other operational tax strategies impacting cash outflows.
General Observations
While reported income tax expenses fluctuated between benefits and expenses, cash taxes paid showed a general increasing trend until a sharp drop in 2024. The divergence between income tax expense and cash operating taxes through the years implies differences between accounting recognition of tax expenses and actual tax payments, which is common in companies with complex tax structures. The decline in both income tax expense and cash operating taxes in 2024 may indicate significant tax planning outcomes or shifts in profitability affecting tax liabilities.

Invested Capital

AbbVie Inc., invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Short-term borrowings
Current portion of long-term debt and finance lease obligations
Long-term debt and finance lease obligations, excluding current portion
Operating lease liability1
Total reported debt & leases
Stockholders’ equity
Net deferred tax (assets) liabilities2
Restructuring reserve3
Equity equivalents4
Accumulated other comprehensive (income) loss, net of tax5
Noncontrolling interest
Adjusted stockholders’ equity
Construction in progress6
Available-for-sale investment securities7
Invested capital

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of restructuring reserve.

4 Addition of equity equivalents to stockholders’ equity.

5 Removal of accumulated other comprehensive income.

6 Subtraction of construction in progress.

7 Subtraction of available-for-sale investment securities.


The financial data over the provided periods reveal several significant trends related to debt, equity, and capital structure.

Total reported debt & leases
The total reported debt and leases exhibit a decreasing trend from 87,063 million USD at the end of 2020 to 60,286 million USD by the end of 2023, reflecting a substantial reduction in leverage over the first four years. However, in 2024, there is a noticeable increase to 68,019 million USD, indicating a reversal of the prior downward trend in debt levels.
Stockholders’ equity
Stockholders' equity initially increases from 13,076 million USD in 2020 to a peak of 17,254 million USD in 2022. Subsequently, it declines sharply to 10,360 million USD in 2023 and continues to deteriorate significantly in 2024, dropping to 3,325 million USD. This steep decrease in equity over the last two years suggests increased challenges with retained earnings or potential capital losses.
Invested capital
Invested capital shows a consistent downward trajectory, reducing from 103,725 million USD in 2020 to 68,204 million USD in 2023. Unlike other trends, invested capital appears to stabilize in 2024 with a slight increase to 69,263 million USD, signaling a possible floor or minor recovery in invested assets or operational capital use.

Overall, the data suggest a focused effort on debt reduction from 2020 to 2023 accompanied by increasing equity till 2022. However, the last two years highlight financial stress with declining equity and rising debt, raising concerns about the company’s capital structure stability and financial leverage. The decline and subsequent stabilization in invested capital corroborate a contraction phase followed by an attempt to maintain or increment operational investment.


Cost of Capital

AbbVie Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt and finance lease obligations3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in millions

2 Equity. See details »

3 Debt and finance lease obligations. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

AbbVie Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


Economic Profit
The economic profit experienced significant fluctuations over the analyzed periods. Initially, there was a substantial negative figure, indicating economic losses. This shifted to positive and stable levels in the following two years, reflecting improved profitability. However, the trend reversed again in the last two periods, returning to negative values but with a reduced magnitude compared to the initial loss.
Invested Capital
There is a consistent downward trend in the invested capital from 2020 through 2023, showing a reduction in the resources allocated in the business. In 2024, this trend slightly changes with a minor increase, suggesting stabilization or cautious reinvestment.
Economic Spread Ratio
The economic spread ratio mirrors the fluctuations observed in economic profit. It starts with a negative return on invested capital, improves to positive values in the subsequent years, and then declines again into negative territory in the final two years. The negative spread in later years, though less severe than initially, indicates a potential challenge in generating returns above the cost of capital.

Economic Profit Margin

AbbVie Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Net revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Net revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


Net Revenues
The net revenues exhibited an overall upward trend from 2020 through 2024. Starting at 45,804 million US dollars in 2020, revenues increased significantly to 56,197 million US dollars in 2021 and continued to rise moderately to 58,054 million US dollars in 2022. Although there was a slight decrease to 54,318 million US dollars in 2023, revenues rebounded to 56,334 million US dollars in 2024. This pattern indicates strong revenue generation capacity with minor fluctuations in the later years.
Economic Profit
The economic profit showed considerable volatility across the five-year period. It began with a substantial economic loss of -3,721 million US dollars in 2020, followed by a strong recovery to a positive profit of 4,013 million US dollars in 2021. The positive economic profit slightly decreased but remained favorable at 3,894 million US dollars in 2022. However, the company faced a downturn in 2023 and 2024, with economic profits declining to negative values of -3,207 million and -2,068 million US dollars, respectively. This pattern suggests challenges in maintaining profitability despite overall revenue growth.
Economic Profit Margin
The economic profit margin mirrors the fluctuations seen in the economic profit figures. Starting at a negative margin of -8.12% in 2020, it improved substantially in 2021 to 7.14% and stayed relatively stable at 6.71% in 2022. Nevertheless, the margin dropped back into negative territory in 2023 (-5.9%) and further declined to -3.67% in 2024. This reflects periods of efficient value creation interspersed with periods of diminished profitability relative to net revenues.
Overall Analysis
The company demonstrated growth in net revenues over the observed period, signaling robust sales performance. Despite this positive revenue trajectory, economic profit and economic profit margin exhibited significant fluctuations, highlighting instability in value creation. The transitions from negative to positive and back to negative economic profit margins suggest varying operational efficiency or cost structures impacting profitability. The recent negative economic profit margins, despite relatively high revenues, could indicate increased costs, investments, or other financial pressures affecting the company’s economic profit generation.